CENTENNIAL, Colo.--(BUSINESS WIRE)--Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that the most recent testing has shown that its ICA-1 compound has demonstrated more exacting specificity of protein kinase C-iota and not of proteins that are closely related to PKC-iota. These results demonstrate greater promise for the development of a targeted therapy. Research being funded by the Company has shown that the ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. The present work performed under a Co-operative Research and Development Agreement (CRADA) with the Department of Veteran’s Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.
